

ERS *monograph*

Guest Editors

Kian Fan Chung



Kian Fan Chung is Professor of Respiratory Medicine and Head of Experimental Studies at the National Heart and Lung Institute, Imperial College London (London, UK). He is also an Honorary Consultant Respiratory Physician at the Royal Brompton and Harefield NHS Trust (London, UK), and a Senior Investigator of the UK National Health Service National Institute for Health Research.

Kian Fan Chung trained in internal and respiratory medicine in London and Oxford (UK), before undertaking post-doctoral training as a Medical Research Council UK Visiting Scientist at the Cardiovascular Research Institute at the University of California San Francisco (San Francisco, CA, USA). He was awarded MD and DSc degrees in 1983 and 2001, respectively, from the University of London (London, UK).

Kian Fan Chung has a major interest in developing precision medicine for chronic obstructive airways disease. His team studies epithelial-macrophage interactions at the airway interface, the effects of mitochondrial oxidant stress, the mechanisms of corticosteroid resistance and the pulmonary impact of environmental pollution and nanoparticles.

He has received research grants from the UK Medical Research Council, the UK National Environmental Research Council, the UK Engineering and Physical Sciences Research Council, the Wellcome Trust, the European Union (EU) Innovative Medicines Initiative, EU Horizon 2020, the US National Institute of Health, the US National Institute for Environmental Health Sciences and the US Health Effects Institute.

Kian Fan Chung serves on the editorial boards of several respiratory and pharmacological journals. He has authored and co-authored more than 800 scientific articles, reviews and book chapters.

Copyright @ERS 2019. Print ISBN: 978-1-84984-103-0. Online ISBN: 978-1-84984-104-7. Print ISSN: 2312-508X. Online ISSN: 2312-5098.

Elliot Israel

Elliot Israel is the Gloria and Anthony Simboli Distinguished Professor in Asthma Research and Professor of Medicine at Harvard Medical School (Boston, MA, USA), and the Director of Clinical Research in the Pulmonary and Critical Care Division at the Brigham and Women's Hospital (Boston, MA, USA). He directs the Brigham and Women's Hospital Severe Asthma Program.

Elliot Israel received his medical degree from the Johns Hopkins University School of Medicine (Baltimore, MD, USA). He completed training in internal medicine at the Johns Hopkins Hospital and Weill Cornell Medical Center at the New York-Presbyterian Hospital (formerly New York Hospital; New York, NY, USA). He undertook fellowships in pulmonary and critical care medicine and allergy and immunology at Harvard Medical School. He is board-certified in allergy and immunology, pulmonary medicine, critical care medicine and internal medicine.

Elliot Israel's research interests include severe asthma, using precision medicine to optimise therapeutic interventions, pharmacogenetic influences on treatment responses, and the role of fatty acid metabolites in asthma pathobiology. He leads a US federally funded study to test novel interventions to narrow disparities in asthma outcomes. At Brigham and Women's Hospital, he is principal investigator of a USA National Institutes of Health-funded initiative to advance precision medicine using adaptive design techniques to identify novel treatments for severe asthma. He leads the protocol design committee of that initiative.

Elliot Israel has authored over 200 peer-reviewed publications and is member of the USA National Asthma Education and Prevention Program (NAEPP) Committee examining asthma guidelines. He is the recipient of the Harvard Medical School Daniel D. Federman Outstanding Clinical Educator Award.

Peter G. Gibson

Peter G. Gibson works as a doctor who cares for people with respiratory diseases and as a clinical scientist investigating the mechanisms and treatment of asthma, COPD, cough and other airway disorders.

He is a concept leader who has developed innovative approaches around: inflammatory subtypes of asthma and cough; airway biomarkers; neurogenic mechanisms, laryngeal dysfunction and related treatments for refractory cough; multidimensional





assessment and management of complex airway disorders such as severe asthma, airways diseases in the elderly; and asthma in pregnant women.

Peter Gibson's research metrics records an H index of 82 (Scopus), 593 published articles and effective mentorship of clinical researchers. He has had continuous research grant funding from the National Health and Medical Research Council (NHMRC), Asthma NSW, MSRP, the Cooperative Research Centre for Asthma and Airways and a successful NHMRC Centres of Research Excellent (CRE) programme.

His peers have awarded him several research medals, including the 2018 European Respiratory Society (ERS) Gold Medal in Asthma, and elected him as the President of the Thoracic Society of Australia and New Zealand (TSANZ; 2015–2016).

His research, clinical practice and participation in guidelines panels serve to bring research developments into focus as effective healthcare interventions that improve the health of people suffering from breathing disorders.